

Sample Review

Subject ID _____

Centralized Pathology Review (CPR) Form Version:

04/14/2022

Batch [batch_number]

CECS Sample ID: [cecs_sample_id]

Originating Facility Block ID: [hospital_block_id]

Path Report Number (Date): [from_path_num] ([from_path_date])

Specimen(s) Received: # Blocks # H&E's # Unstained Slides # Other Slides
[num_blocks] [num_h_and_e] [num_uns_slides] [num_oth_slides]

Batch: _____

CECS Sample ID: _____

Originating Facility Block ID: _____

From Path Report _____

From Path Date _____

Blocks: _____

H & E's: _____

Unstained Slides: _____

Other Slides: _____

Is this sample being reviewed by pathologist?

Yes
 No

Primary evaluation performed by: _____ Date of primary evaluation: _____

Is a secondary pathologist evaluation being performed
for this sample?

Yes
 No

Secondary evaluation performed by: _____ Date of secondary evaluation: _____
 Secondary evaluation: _____ Secondary evaluation comment: _____

Tissue Type? _____ Requested Tissue Type(s): [subj_req_tiss_type]

Source of Reviewed H&E?
 _____ Source of Reviewed H&E Comment: _____

Primary Tumor (Top H&E)

Histologic type of carcinoma?

* Histology is not ideal for clin use in pt care, as it describes an unspecified or outdated diagnosis. Data collectors may use this code only if there is not enough info in the med record to document a more specific diagnosis.

- 8380 Endometrioid adenocarcinoma, NOS / Endometrioid carcinoma, NOS / Endometrioid cystadenocarcinoma
- 8570 Adenocarcinoma with squamous metaplasia / Adenoacanthoma / Endometrioid carcinoma, squamous differentiation
- 8560* Adenosquamous carcinoma / Mixed adenocarcinoma and epidermoid carcinoma / Mixed adenocarcinoma and squamous cell carcinoma
- 8263 Endometrioid carcinoma, villoglandular / Papillotubular adenocarcinoma / Tubulopapillary adenocarcinoma
- 8382 Endometrioid adenocarcinoma, secretory variant
- 8480 Mucinous adenocarcinoma / Colloid adenocarcinoma / Colloid carcinoma / Mucinous carcinoma / Muroid adenocarcinoma / Muroid carcinoma / Mucous adenocarcinoma / Mucous carcinoma
- 8323 Mixed cell adenocarcinoma
- 8441 Serous carcinoma, NOS / Serous cystadenocarcinoma, NOS / Serous adenocarcinoma, NOS / Serous papillary adenocarcinoma, NOS / Papillary serous cystadenocarcinoma / Serous surface papillary carcinoma / Papillary serous adenocarcinoma (NAACCR: Serous endometrial intraepithelial carcinoma - C54._, C55.9)
- 8441/2 Serous endometrial intraepithelial carcinoma (Only "In-situ" histology)
- 8980 Carcinosarcoma, NOS
- 8950* Müllerian mixed tumor
- 8310 Clear cell adenocarcinoma, NOS / Clear cell carcinoma / Clear cell adenocarcinoma, mesonephroid
- 8013 Large cell neuroendocrine carcinoma
- 8020 Carcinoma, undifferentiated, NOS
- 8041 Small cell carcinoma, NOS / Small cell neuroendocrine carcinoma / Small cell carcinoma, pulmonary type (NAACCR: High-grade neuroendocrine carcinoma - C54._, C55.9)
- 8010* Carcinoma, NOS / Epithelial tumor, malignant
- 8140* Adenocarcinoma, NOS
- 8050 Papillary carcinoma, NOS
- 8022 Pleomorphic carcinoma, NOS
- 8460 Papillary serous adenocarcinoma
- 8255* Adenocarcinoma with mixed subtypes / Adenocarcinoma combined with other types of carcinoma
- 8000* Neoplasm, malignant / Tumor, malignant, NOS / Cancer / Malignancy / Unclassified tumor, malignant

- 8575* Metaplastic carcinoma, NOS
- 8951 Mesodermal mixed tumor
- 9111 Mesonephric-like adenocarcinoma

Selected Histology:
[cpr_histology]

Histology (mixed)

- 8380 Endometrioid adenocarcinoma, NOS / Endometrioid carcinoma, NOS / Endometrioid cystadenocarcinoma
- 8570 Adenocarcinoma with squamous metaplasia / Adenoacanthoma / Endometrioid carcinoma, squamous differentiation (NAACCR: Endometrioid carcinoma w/ squamous diff - C54._, C55.9)
- 8560* Adenosquamous carcinoma / Mixed adenocarcinoma and epidermoid carcinoma / Mixed adenocarcinoma and squamous cell carcinoma
- 8263 Endometrioid carcinoma, villoglandular / Papillotubular adenocarcinoma / Tubulopapillary adenocarcinoma
- 8382 Endometrioid adenocarcinoma, secretory variant
- 8480 Mucinous adenocarcinoma / Colloid adenocarcinoma / Colloid carcinoma / Mucinous carcinoma / Muroid adenocarcinoma / Muroid carcinoma / Mucous adenocarcinoma / Mucous carcinoma
- 8441 Serous carcinoma, NOS / Serous cystadenocarcinoma, NOS / Serous adenocarcinoma, NOS / Serous papillary adenocarcinoma, NOS / Papillary serous cystadenocarcinoma / Serous surface papillary carcinoma / Papillary serous adenocarcinoma (NAACCR: Serous endometrial intraepithelial carcinoma - C54._, C55.9)
- 8441/2 Serous endometrial intraepithelial carcinoma (Only "In-situ" histology)
- 8980 Carcinosarcoma, NOS
- 8950* Müllerian mixed tumor
- 8310 Clear cell adenocarcinoma, NOS / Clear cell carcinoma / Clear cell adenocarcinoma, mesonephroid
- 8013 Large cell neuroendocrine carcinoma
- 8020 Carcinoma, undifferentiated, NOS
- 8041 Small cell carcinoma, NOS / Small cell neuroendocrine carcinoma (NAACCR: High-grade neuroendocrine carcinoma - C54._, C55.9)
- 8010* Carcinoma, NOS / Epithelial tumor, malignant
- 8140* Adenocarcinoma, NOS
- 8050 Papillary carcinoma, NOS
- 8022 Pleomorphic carcinoma, NOS
- 8460 Papillary serous adenocarcinoma
- 8000* Neoplasm, malignant / Tumor, malignant, NOS / Cancer / Malignancy / Unclassified tumor, malignant
- 8575* Metaplastic carcinoma, NOS
- 8951 Mesodermal mixed tumor
- 9111 Mesonephric-like adenocarcinoma
- Other1: _____
- Other2: _____
- Other3: _____

Histology Comment

Grade (SEER)? _____
 Grade (SEER) Comment: _____

Grade (SEER): non-endometrioid histologies with missing grade coded as grade 3
 New variable per 2023-08-18 request from Hazel Nichols: "[create a] derived variable (e.g. grade_derived) that inputs 3 for non-endometrioid histologies with missing grade"

Recommended Sectioning Protocol

Recommended sectioning protocol? (Tumor Tissue)
 (Lab Tech will attempt, not guaranteed)

- Full Schema (23 add'l slides can be cut)
 Limited Schema (13 add'l slides can be cut) *Max allowed for Core Biopsies
 Received unstained slides (see count above)
 H&E Only (no add'l slides)

Recommended sectioning protocol? (Normal Tissue)
 (Lab Tech will attempt, not guaranteed)

- Full Schema (10 add'l slides can be cut)
 Limited Schema (5 add'l slides can be cut) *Max allowed for Core Biopsies
 Received unstained slides (see count above)
 H&E Only (no add'l slides)

Recommended Sectioning Protocol Comment

Review of H&E Sections

Top H&E appropriate for molecular analysis?
 (Note: Only requirement for Tumor is >0% Tumor)
 Yes
 No, QNS

Top H&E has \geq 20% tumor nuclei?
 Yes
 No

Next Steps:

Return Top H&Es to PSC w/ preferred sectioning noted Perform digital annotation of Top H&E tumor tissue slides once notified by PSC of image availability Await return of Bottom H&E tumor tissue slides for final review steps

Please circle the tumor component on the Bottom H&E with a permanent marker in preparation for macrodissection. Has the tumor component been circled on the Bottom H&E?
 Yes
 No

Bottom H&E: Approximate tumor nuclei percentage?

(Enter percentage as integer between 0-100)

Bottom H&E sufficient for molecular analysis?
 (Note: Only requirement for Tumor is >0% Tumor)
 Yes
 No, QNS

Has pathologist completed digital annotation of slides?
 Yes
 No

Additional review comments / Notable tissue characteristics: